Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Intermittent oral coadministration of a gamma secretase inhibitor with dexamethasone mitigates intestinal goblet cell hyperplasia in rats.

Aguirre SA, Liu L, Hosea NA, Scott W, May JR, Burns-Naas LA, Randolph S, Denlinger RH, Han B.

Toxicol Pathol. 2014;42(2):422-34. doi: 10.1177/0192623313486315. Epub 2013 May 7.

PMID:
23651588
2.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolites.

Nair SK, Matthews JJ, Cripps SJ, Cheng H, Hoffman JE, Smith C, Kupchinsky S, Siu M, Taylor WD, Wang Y, Johnson TO, Dress KR, Edwards MP, Zhou S, Hosea NA, Lapaglia A, Kang P, Castro A, Ermolieff J, Fanjul A, Vogel JE, Rejto P, Dalvie D.

Bioorg Med Chem Lett. 2013 Apr 15;23(8):2344-8. doi: 10.1016/j.bmcl.2013.02.066. Epub 2013 Feb 24.

PMID:
23489629
3.

Predicting pharmacokinetic profiles using in silico derived parameters.

Hosea NA, Jones HM.

Mol Pharm. 2013 Apr 1;10(4):1207-15. doi: 10.1021/mp300482w. Epub 2013 Mar 7.

PMID:
23427934
4.

Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.

Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S.

Clin Pharmacokinet. 2011 May;50(5):331-47. doi: 10.2165/11539680-000000000-00000.

PMID:
21456633
6.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.

Siu M, Johnson TO, Wang Y, Nair SK, Taylor WD, Cripps SJ, Matthews JJ, Edwards MP, Pauly TA, Ermolieff J, Castro A, Hosea NA, LaPaglia A, Fanjul AN, Vogel JE.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3493-7. doi: 10.1016/j.bmcl.2009.05.011. Epub 2009 May 7.

PMID:
19473839
7.

Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.

Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.

J Clin Pharmacol. 2009 May;49(5):513-33. doi: 10.1177/0091270009333209. Epub 2009 Mar 19.

PMID:
19299532
8.

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.

Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C.

Drug Metab Dispos. 2005 Jan;33(1):165-74. Epub 2004 Oct 22.

PMID:
15502009
9.

Purification of cytochromes P450: products of bacterial recombinant expression systems.

Guengerich FP, Hosea NA, Martin MV.

Methods Mol Biol. 1998;107:77-83. No abstract available.

PMID:
14577214
10.

Factors affecting the clinical development of cytochrome p450 3A substrates.

Gibbs MA, Hosea NA.

Clin Pharmacokinet. 2003;42(11):969-84. Review.

PMID:
12908853
11.

Purification of cytochrome P-450 enzymes.

Bell-Parikh LC, Hosea NA, Martin MV, Guengerich FP.

Curr Protoc Toxicol. 2002;Chapter 4:Unit4.2. doi: 10.1002/0471140856.tx0402s12.

PMID:
23045082
12.

Inactivation studies of acetylcholinesterase with phenylmethylsulfonyl fluoride.

Kraut D, Goff H, Pai RK, Hosea NA, Silman I, Sussman JL, Taylor P, Voet JG.

Mol Pharmacol. 2000 Jun;57(6):1243-8.

PMID:
10825396
13.

Elucidation of distinct ligand binding sites for cytochrome P450 3A4.

Hosea NA, Miller GP, Guengerich FP.

Biochemistry. 2000 May 23;39(20):5929-39.

PMID:
10821664
14.

Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity.

Taylor P, Wong L, Radić Z, Tsigelny I, Brüggemann R, Hosea NA, Berman HA.

Chem Biol Interact. 1999 May 14;119-120:3-15. Review.

PMID:
10421434
15.

Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs.

Guengerich FP, Hosea NA, Parikh A, Bell-Parikh LC, Johnson WW, Gillam EM, Shimada T.

Drug Metab Dispos. 1998 Dec;26(12):1175-8. Review.

PMID:
9860923
16.

Oxidation of nonionic detergents by cytochrome P450 enzymes.

Hosea NA, Guengerich FP.

Arch Biochem Biophys. 1998 May 15;353(2):365-73.

PMID:
9606971
17.

Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.

Shaw PM, Hosea NA, Thompson DV, Lenius JM, Guengerich FP.

Arch Biochem Biophys. 1997 Dec 1;348(1):107-15.

PMID:
9390180
18.
19.

Aspartate 74 as a primary determinant in acetylcholinesterase governing specificity to cationic organophosphonates.

Hosea NA, Radić Z, Tsigelny I, Berman HA, Quinn DM, Taylor P.

Biochemistry. 1996 Aug 20;35(33):10995-1004.

PMID:
8718893
20.

Structural bases for the specificity of cholinesterase catalysis and inhibition.

Taylor P, Radic Z, Hosea NA, Camp S, Marchot P, Berman HA.

Toxicol Lett. 1995 Dec;82-83:453-8. Review.

PMID:
8597093
21.

Specificity and orientation of trigonal carboxyl esters and tetrahedral alkylphosphonyl esters in cholinesterases.

Hosea NA, Berman HA, Taylor P.

Biochemistry. 1995 Sep 12;34(36):11528-36.

PMID:
7547883

Supplemental Content

Loading ...
Support Center